Longitudinal Monocyte Subset Dynamics as Biomarker in Adult Histiocytosis: Association With Mutational Status, Kinase Inhibitor Exposure and Relapse Risk

Hematological Oncology · Published 2026-08-01 · DOI 10.1002/hon.70233

Free full text

Authors (11)

Jerome Razanamahery, Caroline Raymond, Matthias Papo, Francesco Pegoraro, Julien Guy, Ludwig Serge Aho, Jean‐François Emile, Maxime Samson, Sylvain Audia, Julien Haroche, Bernard Bonnotte

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Razanamahery, J., Raymond, C., Papo, M., et al. (2026). Longitudinal Monocyte Subset Dynamics as Biomarker in Adult Histiocytosis: Association With Mutational Status, Kinase Inhibitor Exposure and Relapse Risk. Hematological Oncology. https://doi.org/10.1002/hon.70233

Related articles

• Low‐Dose Chidamide Maintenance Therapy After Hematopoietic Stem Cell Transplantation for T‐Cell Acute Lymphoblastic Leukemia: A Case Series · Hematological Oncology · 2026 · Same journal
• Decoding the Heterogeneity of Diffuse Large B‐Cell Lymphomas: A Comprehensive Genetic, Transcriptomic, and Phenotypic Profiling of B‐Cell Lymphoma Cell Lines · Hematological Oncology · 2026 · Same journal
• Sequential BV‐AVD Therapy in Richter Transformation: Insights Into the Management of Elderly Patients · Hematological Oncology · 2026 · Same journal
• Nucleoporin 98 Rearrangements in Acute Leukemia: A Genomic Landscape Study · Hematological Oncology · 2026 · Same journal
• Trends in Incidence and Survival of Patients With Primary Effusion Lymphoma in the United States: A Population Based Cohort Study · Hematological Oncology · 2026 · Same journal
• Real‐World Treatment Patterns and Healthcare Resource Utilization of Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma in the United States · Hematological Oncology · 2026 · Same journal
• Integrative Transcriptomic and Functional Analysis of PKMYT1 Reveals a Potential Therapeutic Target in Chronic Lymphocytic Leukemia · Hematological Oncology · 2026 · Same journal
• Matching‐Adjusted Indirect Comparison of Gecacitinib, Fedratinib, Pacritinib, and Momelotinib in Second‐Line Myelofibrosis Therapy · Hematological Oncology · 2026 · Same journal
• Clinical Significance of FLT3‐ITD Variation Allele Frequency in Acute Myeloid Leukemia: A Multicenter Study · Hematological Oncology · 2026 · Same journal
• Sustained Complete Response in Refractory Idiopathic Multicentric Castleman Disease Following a Single CD19 CAR T‐Cell Infusion: A Case Report With Mechanistic Insight · Hematological Oncology · 2026 · Same journal